Compare MLEC & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MLEC | RNXT |
|---|---|---|
| Founded | 2008 | 2012 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9M | 36.4M |
| IPO Year | N/A | 2021 |
| Metric | MLEC | RNXT |
|---|---|---|
| Price | $0.21 | $0.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.75 |
| AVG Volume (30 Days) | 162.7K | ★ 185.9K |
| Earning Date | 01-30-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $928,000.00 |
| Revenue This Year | $20.42 | $2,795.35 |
| Revenue Next Year | $30.00 | $272.69 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 170.36 | N/A |
| 52 Week Low | $0.21 | $0.70 |
| 52 Week High | $8.00 | $1.69 |
| Indicator | MLEC | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 20.34 | 46.89 |
| Support Level | $0.21 | $0.89 |
| Resistance Level | $0.34 | $1.00 |
| Average True Range (ATR) | 0.05 | 0.07 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 6.61 | 38.53 |
Moolec Science SA is a science-based ingredient company focused on producing real animal proteins in plants through Molecular Farming, a technology in the alternative protein landscape. Its purpose is to upgrade the taste, nutrition, and affordability of alternative protein products while building a more sustainable and equitable food system. The company has various products in its pipeline such as; TSP Valorasoy which is a soy protein product to produce vegetable proteins with texture and fibrousness similar to those of meat, Glaso, a safflower oil with high levels of gamma-linolenic acid, SPC2 which is a plant-based chymosin, YEEA1, an extract derived from a novel yeast biomass with specific properties, and others. The company's revenues arise from operations in Argentina.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.